Skip to contentSkip to filters

We use cookies for analytics.

Deep Dive: Moving Away From RCTs for Rare Disease Treatment Evaluations

Related content

About

Janet Woodcock and Marshall Summer discuss why conventional randomized trials can be difficult in small and heterogeneous rare-disease populations. They consider designs that use patients as their own controls, the influence of placebo effects and bias, and how natural history and patient input can guide endpoint selection.

Topics

Details

Show

ASCPT Podcast Channel

2 episodes on World Wide · American Society for Clinical Pharmacology and Therapeutics